2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2

Background

Obesity has a controversial effect on BC risk depending on the menopausal status. The mechanisms by which a high BMI protects against BC in premenopausal women are unknown. Adipose tissue produces two antagonistic hormones: leptin activates tumorigenesis in postmenopausal patients; by contrast, adiponectin has an anti-inflammatory effect. The aim of this study is to evaluate adiponectin and leptin levels according to the presence of not of BC in a group of premenopausal women with high BMI.

Methods

This prospective transversal study included premenopausal women with high BMI with recently diagnosed of early BC or without cancer. Age, weight, and height were recorded. Premenopausal status was confirmed by LH, FSH, and estradiol blood values. Fasting values of insulin, glucose, lipid profile, and vitamin D levels were also determined. Adiponectin and leptin levels were analyzed as continuous variable. Adiponectin was also categorized as low, normal, and high considering age and weight. Patients with BC were classified in luminal, triple-negative, and HER2+ by IHC.

Results

Of the 86 women included in the study, 54 were BC-free and 32 with BC (luminal 23, triple-negative 5, and HER2+ 6). Women without cancer had significantly higher BMI (median 32.3 vs 26.8; p<0.001), leptin levels (median 27.3 vs 12.8; p< 0.001), and insulin levels (median 10.8 vs 6.8; p<0.003) than BC patients. However, a significant correlation between high leptin and insulin levels was only observed in BC patients (p<0.001). Furthermore, a significant negative correlation was found between high leptin levels and low vitamin D levels in BC-free women (p<0.004). Conversely, there were no differences in adiponectin levels either as a continuous variable or in the categorization between BC and BC-free women.

Conclusions

This study analyzes, for the first time, the difference between leptin and adiponectin levels in premenopausal women with high BMI with or without BC. Although high leptin levels are associated with an increased risk of BC in postmenopausal women, this does not seem to occur in premenopausal women. Adiponectin levels are similar for both groups.

Clinical trial identification

Editorial acknowledgement

Editorial assistance was provided by Content Ed Net (Madrid, Spain).

Legal entity responsible for the study

The authors.

Funding

Fundación Contigo.

Disclosure

J. Pérez García: Financial Interests, Personal, Advisory Role: Lilly, Roche, Eisai, Daiichi Sankyo, AstraZeneca, Seattle Genetics, Gilead; Financial Interests, Personal, Other, Travel expenses: Roche. J. Cortés: Financial Interests, Personal, Other, Consulting/Advisor: Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, GEMoaB, Gilead, Menarini, Zymework; Financial Interests, Personal, Funding: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, AstraZeneca; Financial Interests, Institutional, Research Funding: Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, Queen Mary University of London; Financial Interests, Personal, Stocks/Shares: MedSIR, Nektar Pharmaceuticals, Leuko (relative); Financial Interests, Personal, Other, Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead; Financial Interests, Personal, Other, Patents: Pharmaceutical Combinations of A Pi3k Inhibitor and A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED Her2 as a predictor of response to dual HER2 blockade in the absence of. L. García Estevez: Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, Daiichi Sankyo, Gilead. All other authors have declared no conflicts of interest.